Table 1. Patient baseline characteristics.
| Characteristic | All (n = 986) | BMI <25 m2/kg (n = 342) | BMI ≥25 to <30 m2/kg (n = 402) | BMI ≥30 m2/kg (n = 242) |
|---|---|---|---|---|
| n (%) or median (interquartile range) | ||||
| Age, years | 75.0 (69.0–81.0) | 77.0 (70.0–83.0) | 75.0 (69.0–80.0) | 73.0 (69.0–78.0) |
| Female sex | 460 (47) | 154 (45) | 170 (42) | 136 (56) |
| Diabetes mellitus | 154 (16) | 37 (11) | 57 (14) | 60 (25) |
| Arterial hypertension | 633 (64) | 182 (53) | 256 (64) | 195 (81) |
| Immobilizationǂ | 217 (22) | 80 (23) | 84 (21) | 53 (22) |
| Chronic pulmonary disease¶ | 135 (14) | 51 (15) | 53 (13) | 31 (13) |
| Cerebrovascular disease** | 91 (9) | 33 (10) | 34 (8) | 24 (10) |
| Heart failure†† | 115 (12) | 41 (12) | 37 (9) | 37 (15) |
| Inflammatory bowel disease | 32 (3) | 15 (4) | 11 (3) | 6 (2) |
| Hemiparesia, hemiplegia, or paraplegia | 28 (3) | 10 (3) | 8 (2) | 10 (4) |
| Prior varicose vein surgery | 136 (14) | 38 (11) | 64 (16) | 34 (14) |
| Type of VTE | ||||
| Provoked | 214 (22) | 77 (23) | 85 (21) | 52 (21) |
| Unprovoked* | 595 (60) | 185 (54) | 250 (62) | 160 (66) |
| Cancer-related† | 177 (18) | 80 (23) | 67 (17) | 30 (12) |
| Prior VTE | 283 (29) | 86 (25) | 114 (28) | 83 (34) |
| Localization of VTE | ||||
| PE±DVT | 682 (69) | 225 (66) | 279 (69) | 178 (74) |
| PE/proximal DVT | 906 (92) | 314 (92) | 364 (91) | 228 (94) |
| Family history of PE/DVT | 165 (17) | 47 (14) | 66 (16) | 52 (21) |
| Estrogen therapy§ | 32 (3) | 16 (5) | 12 (3) | 4 (2) |
| Concomitant antiplatelet therapy¥ | 319 (32) | 104 (30) | 131 (33) | 84 (35) |
| Type of initial parenteral AC | ||||
| LMWH | 464 (47) | 170 (50) | 185 (46) | 109 (45) |
| Unfractionated heparin | 329 (33) | 104 (30) | 133 (33) | 92 (38) |
| Fondaparinux | 158 (16) | 50 (15) | 76 (19) | 32 (13) |
| Danaparoid | 1 (0) | 1 (0) | 0 (0) | 0 (0) |
| None | 34 (3) | 17 (5) | 8 (2) | 9 (4) |
| Initial VKA therapy | 857 (87) | 276 (81) | 363 (90) | 218 (90) |
Abbreviations: BMI = body mass index; VTE = venous thromboembolism; PE = pulmonary embolism; DVT = deep vein thrombosis; AC = anticoagulation; LMWH = Low-molecular-weight-heparin; VKA = vitamin K antagonist.
ǂImmobilization (bed rest >72 hours, fracture or cast of the lower extremity, voyage in sitting position >6 hours) during the last 3 months before index VTE.
¶Chronic obstructive pulmonary disease, active asthma, lung fibrosis, cystic fibrosis, or bronchiectasis.
**History of ischemic or hemorrhagic stroke or hemiparesis, hemiplegia, or paraplegia at the time of screening.
††Known history of systolic or diastolic heart failure, left or right heart failure, forward or backward heart failure, left ventricular ejection fraction of <40%, or acute heart failure (NYHA III/IV) during the last 3 months.
*Any VTE unrelated to cancer or major surgery, immobilization, or estrogen therapy during the last 3 months before index VTE.
†Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, and/or palliative care during the last 3 month before index VTE.
§Estrogen therapy during the last 3 months before index VTE.
¥Use of aspirin, clopidogrel, prasugrel, aspirin/dipyramidol.